NCT01356212 - Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2002

Study Completion Date

December 31, 2002

Conditions

Healthy Subjects

Interventions

DRUG

Ketorolac tromethamine

30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally

DRUG

Ketorolac tromethamine

30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally

DRUG

Ketorolac tromethamine

30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally

Trial Locations (1)

Pharmaceutical Profiles, Ltd, Ruddington